Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Long-Term Deferred Tax: 2022

  • Spyre Therapeutics' Long-Term Deferred Tax was N/A to $566,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $566,000, marking a year-over-year change of. This contributed to the annual value of $566,000 for FY2022, which is N/A change from last year.
  • According to the latest figures from Q4 2022, Spyre Therapeutics' Long-Term Deferred Tax is $566,000.
  • Spyre Therapeutics' Long-Term Deferred Tax's 5-year high stood at $566,000 during Q4 2022, with a 5-year trough of $566,000 in Q4 2022.
  • Over the past 1 years, Spyre Therapeutics' median Long-Term Deferred Tax value was $566,000 (recorded in 2022), while the average stood at $566,000.